SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, speculate on potential rate cuts, and weigh the possibility of S&P 500 inclusion. Community discussions revolve around the stock's potential for growth, with some highlighting its innovative approach to digital banking, while others express concerns about short-term volatility and market manipulation. Bullish sentiment is fueled by expectations of strong performance and positive catalysts, while bears remain cautious.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to news regarding a patient hospitalization which led to trading being temporarily halted, though details remain unclear, leading to speculation around trial impacts and potential buyouts. The community is actively discussing the implications of this event on NTLA and its competitors, alongside long-term prospects for gene editing and upcoming data readouts. Options traders are closely watching the stock, as indicated by LiquidTheta's actionable alerts for LEAPS contracts.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to renewed trading momentum and discussions around its low float. Community members are actively debating potential price targets and short squeeze opportunities, with some comparing it to other Chinese stocks with similar patterns. The stock's high insider ownership and recent revenue growth are also fueling speculation about its future potential.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community members discuss a potential short squeeze, drawing comparisons to other meme stocks like BYND and AMC; some are pointing to a recent tweet from the White House as a possible catalyst. Others in the community are focusing on Ryan Cohen's moves and GameStop's fundamentals. Contrarian views remain, with some users warning about bag holding and potential dilutions.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors anticipate upcoming earnings, with community members weighing in on whether the stock is poised for a significant move.  Discussion also centers on Meta's AI initiatives and potential partnerships, as well as broader speculation about Big Tech's overall performance.  Some traders are eyeing key breakout levels, while others express caution due to the company's capital expenditures.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

UMAC is trending due to growing interest in drone stocks and a recent contract secured by the company. Community members are discussing the company's potential in the drone component supply chain, particularly given its U.S.-based manufacturing and ties to Donald Trump Jr. The broader context involves increasing government spending and policy support for domestic drone production.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to concerns around news impacting the broader gene-editing sector, specifically regarding $NTLA and potential side effects; this has sparked debate about whether to hold or sell. Despite the concerns, some in the community believe this presents a buying opportunity, anticipating positive earnings and data releases, particularly around the November 7th conference, which could drive the stock higher.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amid discussions about its valuation, potential turnaround, and founder Chip Wilson's renewed involvement. Community members are actively debating whether the stock is poised for a rebound or further decline, with some pointing to strong international growth and others citing concerns over tariffs and competition. The stock's price action around the $180 level is also a key focus of conversation.

Smart Logistics Global Ltd. operates as a business-to-business contract logistics provider, specializing in industrial raw materials line-haul transportation. The company develops a smart logistics digital ecosystem for road transport by leveraging innovation, digital analytics, and infrastructure development. It enhances supply chain efficiency, shortens transit times, and improves client visibility using its integrated platform. Its services cater to a diverse range of industries including manufacturing, construction, and FMCG (Fast-Moving Consumer Goods), enabling seamless and cost-effective movement of goods across regional and national networks. The company was founded by Kwok Chiu Hue on October 8, 2020 and is headquartered in Hong Kong.

Smart Logistics Global Ltd.

Smart Logistics Global Limited Ordinary Shares

SLGB is trending due to recent volatility and price swings following its IPO. The stock's low float is fueling speculation of potential for significant moves, with community members actively discussing entry points, possible short squeezes, and price targets. Some traders are also citing the stock as a "China play", drawing comparisons to other Hong Kong-based stocks.

Keurig Dr Pepper, Inc. engages in the manufacture, marketing, distribution, and sales of non-alcoholic beverages. It operates through the following segments: U.S. Refreshment Beverages, U.S. Coffee, and International. The U.S. Refreshment Beverages segment manufactures and distributes beverage concentrates, syrups, and finished beverages including the brands Dr Pepper, Canada Dry, Mott’s, Snapple, A&W, 7UP, Sunkist soda, Squirt, Hawaiian Punch, Core Hydration, Bai, C4 Energy, Clamato, Evian, Yoo-Hoo, Big Red, and Vita Coco. The U.S. Coffee segment involves single serve brewers, specialty, hot and iced varieties, and ready-to-drink beverages. The International segment includes sales in Canada, Mexico, and other markets. The company was founded in 2018 and is headquartered in Burlington, MA.

Keurig Dr Pepper Inc

Keurig Dr Pepper is trending following Q3 earnings, with revenue exceeding expectations and a raised full-year outlook driven by coffee tariff increases. The community is discussing the potential impact of these results and future investor events. Bullish sentiment is fueled by strong sales and future growth prospects, while some analysts remain cautious due to historical performance and market conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why

Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

Investing.com -- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the company’s petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the Generating Antibiotic Incentives Now (GAIN) provisions, has been a significant catalyst for the stock’s movement.

​Retail interest for Phathom Pharmaceuticals soared on Thursday after the company reported first-quarter results, unveiled a sweeping cost-reduction plan and reaffirmed its target to achieve operational profitability by 2026.The company posted Q1 revenue of $28.5 million, slightly below the $29.02 million consensus.&nbsp;Its net loss widened to $94.3 million from $82.9 million a year earlier, driven largely by increased advertising and promotional spend for its lead drug, VOQUEZNA.“2025 will be an inflection point for Phathom,” said CEO Steve Basta.&nbsp;The company announced a 6% workforce reduction, multiple leadership changes, and significant cuts in external spending.&nbsp;Phathom expects the moves to reduce 2025 operating expenses by $60 million to $70 million and lower quarterly spend to under $55 million by the fourth quarter.Basta said the company’s actions are designed to support long-term growth without raising new equity or debt. He added that sales force strength remains a top priority, with commercial personnel now comprising around 75% of the total workforce.Voquezna prescriptions rose 8% sequentially in Q1 to 127,000, while cumulative prescriptions surpassed 390,000 as of April 18.&nbsp;Commercial access remained strong, with coverage extending to over 120 million lives, including more than 80% of commercially insured patients.Phathom also paused its planned Phase 2 trial for eosinophilic esophagitis and is awaiting an FDA decision on its citizen petition seeking full NCE exclusivity through 2032.Retail traders on Stocktwits remained optimistic despite the revenue miss, with sentiment marked as ‘bullish’ amid a 900% surge in 24-hour messaging volume.&nbsp;Several users said they were buying the dip, expressing continued confidence in the company’s long-term prospects.<stembedurl>https://stocktwits.com/DrDare/message/613236534</stembedurl>One user said the volume spike was notable but still lower than on days when major patent or executive updates had occurred.&nbsp;<stembedurl>https://stocktwits.com/Morrito23/message/613282417</stembedurl>They noted persistent concerns over cash burn, but said they welcomed management's move to finally address the issue publicly.Some traders described the first quarter as unusually difficult for pharmaceutical firms, citing formulary changes and deductible resets.&nbsp;Others saw the update as a turning point, with one saying the stock could become a buyout candidate if exclusivity concerns are resolved and revenue momentum continues.<stembedurl>https://stocktwits.com/Canvasback33/message/613238887</stembedurl>Shares of Phanthom have fallen 54.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Packaging and pills of different types of psychotropic medications are seen in this illustration photo taken in Warsaw, Poland on 22 April, 2025. (Photo by Jaap Arriens/NurPhoto via Getty Images)

Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss

Phathom's VOQUEZNA prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 

Equity

Phathom's Voquezna prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 


2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

PHAT
Phathom Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHAT News

PHATPhathom Pharmaceuticals Inc